The ExoDx Prostate IntelliScore (EPI) test is a urine-based screening tool that performs measurably better than PSA alone at predicting whether a prostate biopsy will find clinically significant cancer. Across three independent prospective studies totaling over 1,200 men, the test achieved an area under the curve of 0.70 compared to 0.56 for PSA by itself. But “better than PSA” is a relatively low bar, and the test has real limitations worth understanding before you or your urologist rely on its score.
How the Test Works
The test analyzes RNA extracted from exosomes, tiny vesicles shed by prostate cells, found in a simple urine sample. You provide the first 15 to 50 milliliters of urine at your urologist’s office, without needing a digital rectal exam (DRE) beforehand. That last detail matters: older prostate biomarker tests like PCA3 and the Michigan Prostate Score require a DRE or prostate massage before collection, which adds both discomfort and an extra clinic step. The EPI sample can be collected in a standard office visit with no preparation on your part.
The lab isolates exosomes from the urine and measures expression levels of three genes: PCA3, ERG, and SPDEF. These genes are linked to prostate cancer biology in different ways, and combining their signals captures more information than any single marker alone.1Urology Times. The Role of the ExoDx Prostate Test in Early Detection of Prostate Cancer The test feeds these gene-expression readings together with standard clinical information (PSA level, age, race, family history) into an algorithm that generates a score on a 0–100 scale. A score at or above 15.6 is considered positive, flagging higher risk of harboring high-grade prostate cancer, defined as Gleason Grade Group 2 or higher.
Accuracy Numbers from Clinical Trials
The most comprehensive look at accuracy comes from pooled data across three prospective validation studies. In a combined cohort of 1,212 men, the EPI test at the 15.6 cutoff had a negative predictive value (NPV) of 90%, meaning that when the test said low risk, it was correct about 9 times out of 10. Sensitivity was 92%, so the test caught the vast majority of high-grade cancers. The positive predictive value sat at roughly 36%, which means most men who score positive will not actually have high-grade disease on biopsy.2Prostate Cancer and Prostatic Diseases. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies
Those numbers deserve context. An NPV of 90% sounds reassuring, and for most men stuck in the gray zone of PSA screening, it is. But it also means roughly 1 in 10 men told they are low-risk do have significant cancer. The test’s primary value is in ruling out high-grade cancer confidently enough to skip or delay a biopsy, not in confirming cancer is present.
A separate, smaller real-world study of 113 men reported somewhat different numbers: sensitivity of about 77%, specificity of 66%, NPV of 77%, and positive predictive value of 33%.3PubMed Central. Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis The gap between these findings and the larger validation studies likely reflects differences in patient mix and biopsy protocols, but it is a useful reminder that real-world performance can drift from trial results.
An alternative cutoff of 20 has also been studied. At this higher threshold, the test would avoid about a third of all biopsies, with an NPV of 89% and sensitivity of 87%. The tradeoff is that more high-grade cancers would be missed, roughly 11% of Grade Group 2 or higher cancers compared with 7–8% at the 15.6 cutoff.4PubMed. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy Some urologists use this higher cutoff for patients who are especially anxious about biopsy, but the 15.6 threshold remains the standard validated score.
How It Compares to PSA and Other Tools
PSA alone is a notoriously blunt instrument for distinguishing dangerous prostate cancer from harmless findings. In the pooled validation data, PSA had an AUC of 0.56, barely better than a coin flip for separating high-grade cancer from benign tissue or low-grade disease. The commonly used Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) scored an AUC of 0.62, and the European Randomized Study for Screening Prostate Cancer Risk Calculator (ERSPC-RC) managed 0.59. The EPI test’s AUC of 0.70 represents a meaningful step up from all three.2Prostate Cancer and Prostatic Diseases. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies That said, an AUC of 0.70 is good, not great. It means the test gets the ranking right between a cancer patient and a non-cancer patient about 70% of the time.
Among the broader landscape of prostate cancer biomarkers, the EPI test occupies a middle tier. A comparison framework published in BJUI Compass found that serum-based biomarkers like the 4Kscore and the Prostate Health Index (phi) generally had higher discriminative accuracy than urine-based tests, including the EPI. The 4Kscore scored highest for overall utility. Among urine tests, the EPI had better usability than the Michigan Prostate Score, largely because it skips the DRE requirement, but its validity and utility scores were somewhat lower.5PubMed Central. Comparing diagnostic prostate cancer biomarkers using a framework of clinically meaningful criteria The serum-based tests require a blood draw rather than a urine sample, so the practical choice often comes down to what your urologist offers and how the test fits into your overall diagnostic workup.
How It Changes Biopsy Decisions in Practice
The most practical question for patients is whether the test actually changes what happens next. A prospective clinical utility trial of 458 men in the EPI arm found that it clearly did. Among men who scored below 15.6, about two-thirds were advised by their urologist to skip the biopsy, and 92% of those men followed that advice. Among men who scored at or above 15.6, 87% were advised to proceed with biopsy, and 72% complied. Across the full EPI arm, about two-thirds of urologists reported that the test influenced their biopsy decision.6PubMed Central. Clinical utility of the exosome based ExoDx Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL
The downstream effects were meaningful. The EPI arm detected about 30% more high-grade cancers compared to the standard-of-care control arm, and the researchers estimated that roughly half as many significant cancers were missed due to biopsy deferrals compared to standard practice.7Prostate Cancer and Prostatic Diseases. Clinical utility of the exosome based ExoDx ProstateIntelliScore EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL That might seem counterintuitive — how does a test designed to reduce biopsies end up catching more cancers? The answer is that it steers biopsies more efficiently. Men at higher risk were more likely to actually get the biopsy, while men at lower risk (who were clogging the system with unnecessary procedures) were more likely to defer.
Patient engagement also improved. About 80% of urologists shared the EPI report directly with their patient, and 98% of both doctors and patients found the report easy to understand.7Prostate Cancer and Prostatic Diseases. Clinical utility of the exosome based ExoDx ProstateIntelliScore EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL Having a concrete number to discuss, rather than the ambiguity of a mildly elevated PSA, seems to help patients participate more actively in the biopsy decision.
A follow-up analysis reinforced these patterns. Among men in the EPI arm, those with low-risk scores were much less likely to undergo biopsy than those with high-risk scores (about 45% vs. 79%). In the control arm, where urologists did not see EPI results, biopsy rates were essentially identical regardless of what the hidden EPI score would have been, around 59% in both groups.8PubMed Central. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis The takeaway is that EPI adds genuinely new information that standard clinical factors alone do not capture.
Performance in African American Men
Prostate cancer hits African American men harder than almost any other group, with higher incidence, earlier onset, and more aggressive disease on average. Whether a screening test performs reliably across racial groups is not a footnote; for many families it is the whole question.
A study of 156 men examined the combined diagnostic value of the EPI test and pre-biopsy MRI in both African American and non-African American patients. Among African American men with both a positive EPI score and a high-suspicion MRI finding (PI-RADS 4 or 5), the risk of clinically significant cancer was about 86%, substantially higher than the 50% seen in non-African American men with the same combination.9Journal of Clinical Oncology. Predictive capability of combining ExoDx (EPI) and pre-biopsy prostate MRI in detecting clinically significant prostate cancer in African American men The researchers noted that a positive EPI score significantly increased the predicted risk of significant cancer among African American men compared to non-African American men when both had suspicious MRI findings. That disparity is clinically useful: it suggests the combination of EPI and MRI could be especially valuable for risk stratification in a population that tends to face the most aggressive disease.
Additional data from the clinical utility trial showed that among African American men in the EPI arm, 41.6% were diagnosed with high-grade prostate cancer over a 2.5-year follow-up, compared with about 30% in the standard-of-care arm. The higher detection rate was driven by more men with high-risk scores actually getting biopsied rather than deferring, a pattern consistent with the test’s intended use.
Repeat Biopsies and Active Surveillance
Many men who need this kind of test most are those who have already endured one negative biopsy and face the question of whether to do it again. A study of 229 men with a prior negative biopsy found that the EPI test performed well in this repeat-biopsy setting, delivering an NPV of 92% at the 15.6 cutoff. The test would have avoided about 26% of unnecessary repeat biopsies while missing only five patients with high-grade cancer out of the entire group.10PubMed Central. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy At a higher cutoff of 29.6, the test could have delayed over 60% of unnecessary biopsies in that population, though with a wider net of missed cases.
For men already diagnosed with low-grade prostate cancer (Gleason Grade Group 1) and enrolled in active surveillance, preliminary multi-center data suggest the EPI test may help predict who is harboring hidden higher-grade disease. As standalone tools, the EPI test and MRI performed similarly, each with NPVs around 78–80%. But in men whose MRI showed no suspicious findings (PI-RADS 1 or 2), the EPI test’s NPV reached 100% in that subset, meaning every man with a low EPI score and a clean MRI truly had only low-grade disease on biopsy.11Urologic Oncology: Seminars and Original Investigations. EVALUATING EXODX PROSTATE TEST IN MEN WITH LOW-GRADE PROSTATE CANCER ON ACTIVE SURVEILLANCE – A MULTI-CENTER PROSPECTIVE TRIAL The numbers in this study are small and the work is early-stage, but the combination could eventually help some men on surveillance avoid confirmatory biopsies altogether.
What the Test Can Miss
No screening test catches everything, and the EPI test’s published miss rates are worth understanding clearly. In the pooled cohort of 1,212 men, using the 15.6 cutoff, about 2.3% of all men tested would experience delayed detection of Grade Group 2 or higher cancer. For the more aggressive Grade Group 3 or higher cancers, the 15.6 cutoff identified 93% of cases. If your score fell below 15.6, the chance of missing a Grade Group 3 or higher cancer on biopsy was about 4%.2Prostate Cancer and Prostatic Diseases. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies
At the higher cutoff of 20, which spares more men from biopsy, the miss rate for Grade Group 3 or higher rises to about 5% of men below that threshold. In absolute terms, the pooled data show 12 to 19 men out of 1,212 would have had their high-grade cancer detected later rather than immediately. Those numbers are small, but they are not zero. A negative EPI score is not a guarantee of a cancer-free prostate. It shifts the probability substantially in your favor, which is why most urologists treat it as one input into a shared discussion rather than a standalone verdict.
The test is also designed for a specific clinical window: men with PSA levels between 2 and 10 ng/mL who are being considered for an initial or repeat biopsy. Outside that range, the validation data simply do not apply. Men with very high PSA levels, those with known cancer weighing treatment decisions, or those being evaluated after treatment for recurrence are not the intended users. If your PSA is above 10 and your urologist orders an EPI test, it is reasonable to ask how the result should be interpreted given the limited evidence at that PSA level.
Cost and Insurance Coverage
From a health-economics perspective, using biomarkers like the EPI test before biopsy tends to save money compared to biopsying every man with an elevated PSA. A systematic review of cost-effectiveness models in prostate cancer found that all 11 studies comparing biomarker-guided strategies to PSA-only approaches concluded that biomarkers were cost-saving.12PubMed Central. Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis A dedicated analysis estimated that the EPI test provided the highest quality-adjusted life years among the biomarkers compared, with an incremental cost-effectiveness ratio of about $58,000 per quality-adjusted life year, well within the threshold typically considered acceptable in the United States.13PubMed. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis
That said, the cost-effectiveness picture is not uniform. A separate economic evaluation that compared several urine-based and MRI-based strategies found that other urine markers like PCA3 were more likely to be cost-effective at common willingness-to-pay thresholds, suggesting the ranking depends heavily on which alternatives are being compared and the assumptions built into the model.14PubMed Central. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States
The test currently has a list price of around $760, though this can vary. Medicare covers it for eligible patients. Private insurance coverage remains inconsistent, and out-of-pocket cost is one of the most common complaints patients report in online discussions. If you are considering the test and cost is a concern, confirming coverage with your insurer before the sample is collected is the single most important step. The sample itself requires no special preparation. It can be refrigerated for up to two weeks before shipping to the company’s CLIA-certified laboratory, where exosome isolation and RNA extraction are performed centrally.10PubMed Central. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy
Where the Test Fits in the Larger Diagnostic Pathway
The EPI test is not replacing PSA, MRI, or biopsy. It occupies a specific niche: the gap between an elevated PSA and the decision about whether to stick a needle in your prostate. For men with PSA in the 2–10 ng/mL range, which captures the vast majority of patients in this gray zone, the test adds information that PSA and standard risk calculators cannot provide on their own. The strongest evidence supports using it before a first biopsy or before a repeat biopsy in men with a prior negative result.
Combining EPI with MRI appears to be the direction the field is headed. Early data in both the active surveillance and African American subpopulations suggest that using both tools together identifies high-risk patients more accurately than either tool alone. Whether that combination becomes standard practice will depend on larger confirmatory studies and on practical questions like cost, clinic workflow, and insurance coverage that have nothing to do with the biology of exosomes.
For now, if your urologist recommends the EPI test, the evidence supports it as a useful addition to the decision-making process. It is particularly strong as a rule-out tool: a low score, combined with clinical judgment, provides reasonable confidence to defer a biopsy and monitor instead. A high score does not mean you have cancer; it means the biopsy is worth doing. The test works best when both you and your doctor treat it as one piece of the puzzle rather than the final word.